FDA announces Class I recall of ventilators after 3 patient injuries

The U.S. Food and Drug Administration (FDA) has issued a recall on behalf of ventilator manufacturer Percussionaire after a nickel coating was found on the breathing circuits of one of its products. Nickel can react to various drugs used in conjunction with the mechanical ventilator, causing lung injury, airway spasm, anaphylaxis, and possibly death.

There have been three reported injuries associated with use of the Intrapulmonary Percussive Ventilation (IPV) Phasitron 5 breathing circuit. No one has died. However, because of the serious risks the defect poses to patient health, the recall has been given a Class I designation, reserved for the most serious type. 

What is being recalled?

Certain lots of the Percussionaire Phasitron 5 ventilators are subject to the recall. More specifically, the breathing circuits are being recalled because of the nickel coating. 

Percussionaire Phasitron 5 

Here are the recalled part/lot numbers:

  • P5-10/240329, 240412,240430, 240509, 240516, 240614, 240625 
  • P5-HC-5/240321
  • P5-UC-10/240627

Patients and providers are to cease using the devices immediately. 

Next steps

If there’s an emergency situation and recalled Phasitron 5 ventilators must be used, the FDA and Percussionaire have updated safety instructions that operators should follow:

  • Rinse with sterile water after use and allow the ventilator to air dry.
  • Only use saline as the liquid in the nebulization cup.
  • Stop use if unexpected symptoms occur.
  • Do not use the ventilator to deliver medications.
  • Do not use it for more than 2 weeks.
  • Do not use it on any patient in an inflammatory state. 

The company said all customers have received a notice of the recall with instructions on how to obtain replacements. 

The full recall notice can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.